Patient‐reported 
ADVERSE EVENT
Among these patients, a total of 174 AEs were reported, and 66.7% of patients experienced an AE with at‐home ocrelizumab infusion (Fig. Post‐infusion (A) patient‐reported AEs and (B) most common patient‐reported AEs. AE, adverse event; GI gastrointestinal.